KIF26B and cancer: Results indicated that tumor size (HR: 1.933, 95% CI: 1.108–3.372, P = 0.02), Lymph node status (HR: 3.546, 95% CI: 1.815–6.928, P<0.001), clinical stage (HR: 2.940, 95% CI:1.680–5.144, P<0.001), grade (HR: 2.000, 95% CI: 1.104–3.624, P = 0.022) and KIF26B (HR: 1.919, 95% CI: 1.198–3.067, P = 0.006) as significant predictors of cancer-specific survival.